Menu
Not yet recruiting NCT06713655

Predicting Treatment Failure in HSIL Patients with Positive Margins After Conization Via Detection of PAX1 Methylation

— Observational High-grade Squamous Intraepithelial Lesions (HSIL) Cervical Conization

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: High-grade Squamous Intraepithelial Lesions (HSIL), Cervical Conization. Basic parameters: 26 years — 54 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Multicenter Study on PAX1 Methylation for Predicting Lesion Persistence/Recurrence in HSIL Patients with Positive Margins After Cervical Conization

Overview

The goal of this multicenter, observational study is to evaluate whether methylation testing of paired box gene 1 (PAX1) can better predict and diagnose recurrence or persistent disease in patients with positive margins after cervical conization for high-grade squamous intraepithelial lesion (HSIL). The main question it aims to answer is: Can PAX1 gene methylation testing provide a more accurate and effective prediction and diagnosis of cervical disease recurrence/persistence in addition to existing methods? Participants will be managed according to the latest clinical guidelines, and during follow-up, a non-invasive test, PAX1 gene methylation testing, will be added.

Detailed description

This study is a multicenter, prospective observational study that qualitatively assesses the methylation status of the PAX1 gene in cervical exfoliated cells from patients with HSIL and positive margins after conization. The aim is to evaluate the ability of PAX1 gene methylation testing to predict treatment failure (lesion recurrence or persistence). The first follow-up occurs 6 months post-surgery, including high-risk human papillomavirus (hrHPV) testing and cytology, with referral for colposcopy, including biopsy and/or endocervical curettage (ECC), if necessary. Subsequent management and follow-up are based on examination results, following clinical guidelines, and arranged at intervals of 6-12 months depending on the findings. The follow-up includes routine clinical examinations widely applied in practice, and PAX1 testing will be completed at each follow-up visit. PAX1 testing, like hrHPV testing and cytology, will be performed using cervical exfoliated cells.

Primary outcome measures

  • Treatment failure rate within 24 months after surgery (cervical intraepithelial neoplasia grade 2+ (CIN2+) recurrence/residual rates) [Time frame: 2 years post-surgery]
  • Sensitivity of the PAX1 methylation to detect treatment failure [Time frame: 2 years post-surgery]
  • specificity of the PAX1 methylation to detect treatment failure [Time frame: 2 years post-surgery]

Eligibility criteria

Inclusion criteria

  • Age greater than 25 years and less than 55 years;
  • First-time cervical conization (cold knife conization or loop electrosurgical excision procedure);
  • Postoperative pathology showing HSIL (CIN2 or CIN3);
  • Positive margins for HSIL (CIN2 or CIN3) in conization specimen.

Exclusion criteria

  • The presence of other malignant tumors or precancerous lesions;
  • Lack of willingness for follow-up;
  • Pregnant or breastfeeding women;
  • Unable or unwilling to complete follow-up examinations;
  • History of prior cervical disease treatment (surgical or physical therapy);
  • Presence of immune system disorders.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Women's Hospital School Of Medicine Zhejiang University — Hangzhou

Identifiers

NCT: NCT06713655 · IRB-20240248-R

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗